EZH2 and cancer: One of the key players targeting PRC2 activity in cancer treatment is enhancer of zeste homologue 2 (EZH2), which is an enzymatically active subunit of the PRC2 complex that methylates H3K27 to promote chromatin compaction and transcriptional silencing (see reviews by Margueron and Reinberg [178] and Di Croce and Helin [179]).